BMJ

Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group

20 Amsterdam Rheumatology & Immunology Center, Academic Medical Center, Amsterdam, The Netherlands Correspondence to Dr Robert G W Lambert, Department of Radiology and Diagnostic Imaging, University ...
BMJ

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

2 Rheumatology Department, Leiden University Medical Center, Leiden, The Netherlands 3 Rheumatology Department, Maastricht University Medical Center, Maastricht, The Netherlands Background The ...
BMJ

Purine-rich foods intake and recurrent gout attacks

1 Clinical Epidemiology Research and Training Unit, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA 2 Data Coordinating Center, Boston University School of ...
BMJ

EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis

15 Department of Radiology. Leiden University Medical Centre, Leiden, The Netherlands 16 Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands ...
BMJ

OP0039 ALPN-303, AN ENHANCED, POTENT DUAL BAFF/APRIL ANTAGONIST ENGINEERED BY DIRECTED EVOLUTION FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS ...

1 Alpine Immune Sciences, Translational Sciences, Seattle, United States of America 2 Alpine Immune Sciences Inc, Immunology, Seattle, United States of America 3 Alpine Immune Sciences Inc, Clinical ...
BMJ

AB1069 URIC ACID LEVELS IN RELATION TO FASTING BLOOD GLUCOSE AND HbA1c

2 Farhat Hached Hospital, Endocrinology and Diabetes Department, Sousse, Tunisia Background Hyperuricemia is reported to be a risk factor for the development of type 2 diabetes (T2D) and prediabetes.
BMJ

POS1128 COMBINATION TREATMENT OF AR882, A NEW URAT1 INHIBITOR, AND XANTHINE OXIDASE INHIBITORS ALLOPURINOL OR FEBUXOSTAT: EFFECT ON URIC ACID ...

Background: Xanthine oxidase inhibitors (XOI) are commonly used as urate lowering therapy (ULT) for the treatment of gout. Allopurinol, the first-line treatment, demonstrates low response rate (< 40%) ...
BMJ

Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?

We read with great interest the recent paper by Aranow et al 1 about the impact of laboratory results on scoring of the Physician Global Assessment (PGA) of disease activity in systemic lupus ...
BMJ

CD-19 CAR-T cells for polyrefractory rheumatoid arthritis

‘Poly-refractory’ disease affects 2.7% of patients with rheumatoid arthritis (RA) who have failed different groups of biologic disease-modifying antirheumatic drugs (b-DMARDS) and targeted synthetic ...
BMJ

Relationship between serum urate and changes in dual-energy CT monosodium urate crystal volume over 1 year in people with gout: an individual participant data analysis

Objectives The dynamics of monosodium urate (MSU) crystal changes across a range of serum urate concentrations in people with gout are unknown. This study aimed to systematically examine the ...
BMJ

Correspondence on ‘Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial’

Correspondence to Xiaoqing Peng, Department of Obstetrics and Gynaecology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, China; pengxiaoqing{at}ahmu.edu.cn We read with ...